After the spin-off, Sandoz will become the largest listed generics company in Europe, headquartered in Switzerland

Recently, Novartis announced that it plans to 100% divest its generic and biosimilar drug division Sandoz (Sandoz) into a newly listed independent operating company, which is expected to complete the spin-off process in the second half of 2023

Recently, Novartis announced that it plans to 100% divest its generic and biosimilar drug division Sandoz (Sandoz) into a newly listed independent operating company, which is expected to complete the spin-off process in the second half of 2023

Novartis said that after the spin-off Sandoz will become Europe's largest listed generic drug company, headquartered in Switzerland, will be listed on the SIX Swiss Exchange, and implement the American Depositary Receipt (ADR) program in the United States

In fact, as early as 2019, the former Novartis CEO Richard Francis announced that he was preparing to spin off Sandoz when he left office

Earlier this year, foreign media reported that private equity firms Blackstone Group and The Carlyle Group may join forces to buy Sandoz for $25 billion

Earlier this year, foreign media reported that private equity firms Blackstone Group and The Carlyle Group may join forces to buy Sandoz for $25 billion

Now, Sandoz's whereabouts have finally settled

The split is the latest move by Novartis to shift its strategic focus and will allow the company to focus more on developing and manufacturing breakthrough treatments

Vas Narasimhan MD, CEO of Novartis, said: "For Novartis, the spin-off of Sandoz will further support our strategy of building an innovative drug company that will strengthen our 5 core therapeutic areas (hematology, solid tumors, immunology) , Neuroscience and Cardiovascular), as well as the strength of technology platforms (gene therapy, cell therapy, radioligand therapy, targeted protein degradation, and xRNA)

Sandoz, with sales of $9.

Sandoz currently has a pipeline of 15 biosimilars, with top-selling biosimilars including Neupogen, Enbrel, Neulasta and Humira, as well as about 1,000 other molecules used to treat different diseases
.

Sandoz currently has a pipeline of 15 biosimilars, with top-selling biosimilars including Neupogen, Enbrel, Neulasta and Humira, as well as about 1,000 other molecules used to treat different diseases
.